Feb 7 (Reuters) - Paion AG PA8G.DE
* Capital increase; preliminary, unaudited key group
financial figures for 2016
* Net loss in 2016 amounted to 20.1 million euros (previous
year: net loss of 28.2 million euros)
* Revenues in 2016 amounted to 4.3 million euros (previous
year: 0.1 million euros)
* Cash and cash equivalents amounted to 30.1 million euros
as of 31 december 2016 (31 december 2015: 32.7 million euros)
* Should development, filing and approval through cosmo in
procedural sedation in U.S. go according to plan, paion will not
need additional funding to bring remimazolam to U.S. Market
Source text for Eikon: ID:nEQ45LwGJ
Further company coverage: PA8G.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))